Latest News


Genmab is actively seeking partners interested in developing novel antibody therapeutics incorporating its proprietary technologies.

Genmab is particularly interested in the possibility of participating in development of products in oncology and hematology that utilize Genmab’s technologies, in addition to providing commercial technology licenses in exchange for upfront payments, milestones and royalties.

Therapeutics based on innovative antibody platforms, such as the DuoBody and HexaBody technologies, have potential application in multiple disease areas. We believe this makes these technologies of broad interest to potential partners. To facilitate evaluation of the DuoBody and HexaBody technologies before making a commitment to clinically develop and commercialize products, Genmab can also provide research licenses. These licenses permit in-depth investigation of multiple product concepts in a non-clinical setting.

Click here to request more information.